Lantheus to divest SPECT business to SHINE Technologies by end-2025
Jan 1, 2026, 4:59:59 AM — merger close
Summary
Lantheus Holdings has entered a definitive agreement to sell its SPECT (single photon emission computed tomography) business, including diagnostic agents TechneLite, NEUROLITE, Xenon Xe-133 Gas, and Cardiolite, to SHINE Technologies. The transaction includes related manufacturing facilities and Canadian operations, and is expected to close by year-end 2025, subject to customary conditions. Lantheus will receive upfront cash, a convertible note, and potential earnouts. The divestiture will allow Lantheus to focus on PET radiodiagnostics and its radiopharmaceutical pipeline, while SHINE expands its nuclear medicine platform. SPECT products are used for diagnostic imaging in cardiology and neurology.
Company
LANTHEUS HOLDINGS INC (LNTH)NASDAQ — Healthcare: Manufacturing, Drug Manufacturers - Specialty & Generic: In Vitro & In Vivo Diagnostic Substances
www.lantheus.comSimilar Events
Transaction Closing Date
The merger between Ligand Pharmaceuticals and Channel Therapeutics is expected to close in the summer of 2025, enhancing the focus on ZELSUVMI commercialization.
merger closeNDA Submission for MK-6240
Lantheus plans to file a New Drug Application for MK-6240, a tau PET radiodiagnostic, with the FDA in Q3 2025, following successful pivotal study results.
fda decisionMerger Agreement between Pelthos Therapeutics and Channel Therapeutics
Ligand Pharmaceuticals' subsidiary Pelthos Therapeutics is set to merge with Channel Therapeutics, with a transaction expected to close in summer 2025.
merger closeMerger Agreement with 20/20 BioLabs, Inc.
Longevity Health Holdings has announced a merger with 20/20 BioLabs, expected to close in Q3 2025, enhancing its diagnostics and product portfolio.
merger close